We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Albireo Pharma, Inc. (“Albireo” or the “Company”) (NASDAQ: ALBO), in connection with the proposed acquisition of the Company by Ipsen S.A. (OTC: IPSEY) via tender offer.  Under the terms of the merger agreement, the Company’s shareholders will receive $42.00 in cash for each share of Albireo common stock owned, plus one contingent value right (“CVR”) per share. Each CVR will entitle its holder to deferred cash payments of $10.00 per CVR.

Weiss Law is investigating whether (i) Albireo’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $42.00 per share merger consideration adequately compensates Albireo’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.  Notably, at least one analyst set a price target for the Company of $59 per share, $17.00 above the per-share merger consideration.